[go: up one dir, main page]

MX2022004678A - Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. - Google Patents

Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2022004678A
MX2022004678A MX2022004678A MX2022004678A MX2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A
Authority
MX
Mexico
Prior art keywords
beta
disease
treating alzheimer
amyloid antibody
amyloid
Prior art date
Application number
MX2022004678A
Other languages
English (en)
Inventor
Thierry Bussiere
Roger Nitsch
Haeberlein Samantha Budd
Ying Tian
Laura Nisenbaum
Raj Rajagovindan
Gersham Dent
John Beaver
Edward Plowey
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2022004678A publication Critical patent/MX2022004678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos para tratar la enfermedad de Alzheimer en un sujeto humano que lo necesite que comprenden la administración de dosis múltiples de un anticuerpo anti-beta amiloide (por ejemplo, aducanumab) al sujeto.
MX2022004678A 2019-10-22 2020-10-21 Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. MX2022004678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2022004678A true MX2022004678A (es) 2022-08-15

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004678A MX2022004678A (es) 2019-10-22 2020-10-21 Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US20220372123A1 (es)
EP (1) EP4048695A1 (es)
JP (1) JP2022553329A (es)
KR (1) KR20220084095A (es)
CN (1) CN114599393A (es)
AU (1) AU2020371612A1 (es)
BR (1) BR112022007595A2 (es)
CA (1) CA3158513A1 (es)
CO (1) CO2022004902A2 (es)
IL (1) IL292363A (es)
JO (1) JOP20220092A1 (es)
MX (1) MX2022004678A (es)
WO (1) WO2021081101A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
EP4426349A4 (en) * 2021-11-03 2025-10-29 Biogen Ma Inc METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE
US20250377367A1 (en) * 2022-02-02 2025-12-11 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN120548191A (zh) * 2022-10-25 2025-08-26 基础科学研究院 促进脑脊液排出的颅外方法
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2439490T3 (es) 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
EP2152309B1 (en) * 2007-05-14 2013-07-10 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN103179981B (zh) * 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
BR112014006376B1 (pt) * 2011-09-19 2021-07-27 Axon Neuroscience Se Anticorpo isolado que se liga a um ou mais epítopos tau, ácido nucleico, vetor, composição farmacêutica, artigo de fabricação, dispositivo médico, método in vitro para diagnosticar ou triar um indivíduo quanto à presença de doença de alzheimer ou de uma tauopatia relacionada e usos do referido anticorpo
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MA45149A (fr) * 2016-06-07 2019-04-10 Biogen Int Neuroscience Gmbh Méthodes de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
WO2021081101A1 (en) 2021-04-29
EP4048695A1 (en) 2022-08-31
JOP20220092A1 (ar) 2023-01-30
KR20220084095A (ko) 2022-06-21
JP2022553329A (ja) 2022-12-22
AU2020371612A1 (en) 2022-05-19
IL292363A (en) 2022-06-01
BR112022007595A2 (pt) 2022-08-23
US20220372123A1 (en) 2022-11-24
CO2022004902A2 (es) 2022-07-08
CA3158513A1 (en) 2021-04-29
CN114599393A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
ZA202107358B (en) Method for treating alzheimer's disease
MX2021002321A (es) Nuevos metodos.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
MY184890A (en) Improved a? protofibril binding antibodies
MY187358A (en) Modified release orally administered amino acid formulations
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
WO2017142895A8 (en) Compositions and methods for treating clostridium associated diseases
AR119159A1 (es) Tratamientos de angioedema
MY206426A (en) Anti-cd38 antibodies and formulations
WO2023081194A3 (en) Methods for treating alzheimer's disease
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
EP4461361A3 (en) Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
WO2020092533A3 (en) Methods of treatment using anti-cd123 immunoconjugates
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.